To find out more about the podcast go to The Life Scientific: Asel Sartbaeva.
Below is a short summary and detailed review of this podcast written by FutureFactual:
Room-Temperature Vaccines: Silica Coats Stabilize Proteins for Global Immunisation
What is this episode about
In this Life Scientific episode, Asil Satbhaiva explains insilication, a silica coating that protects vaccine proteins from heat-induced unfolding. The approach could allow vaccines to be stored and transported at room temperature, reducing reliance on cold chains and improving access in low-resource settings. The conversation traces Satbhaiva's remarkable journey from Kyrgyzstan to the UK, the science behind silica coatings, and the early demonstrations in proteins and tetanus vaccines that signal real-world potential.
Key insights
- Thermal stability of vaccines is a major barrier to global distribution, especially in LMICs.
- A bespoke silica shell can prevent protein unfolding, maintaining biological activity at higher temperatures.
- Proof-of-concept experiments show preserved activity in coated proteins and immune response with coated tetanus vaccine in mice.
- Development raises questions about safety, regulatory pathways, and commercialisation, but could transform vaccine delivery at scale.
Overview and context
The podcast features Asil Satbhaiva, an associate professor of Chemistry at Bath University, discussing insilication, a novel approach to stabilise vaccines by coating proteins with a silica shell grown around them. This idea grew from Satbhaiva’s background in silica chemistry and her personal observation during a routine vaccination of her infant daughter. The discussion situates the work within the larger public health challenge: vaccines require cold storage from manufacture to administration, and breakdowns along distributions channels lead to significant waste and preventable disease, especially in lower income countries.
From Kyrgyzstan to Cambridge to Bath
Satbhaiva’s life story forms a thread through the episode. Born in 1977 in Kyrgyzstan, she describes growing up under Soviet rule with scarcity and queues for bread and milk. Her drive to study technical subjects came from a desire for stability and a belief that numbers and facts are less easily manipulated. She pursued a combined undergraduate and master’s degree in natural sciences at Kyrgyzstan’s Kyrgyz Russian Slavic University, faced gender barriers in competition and academia, and later moved to the UK on a full scholarship for a PhD in mineral physics at Cambridge. There she studied silica-based minerals, including quartz, and collaborated with her husband Stephen Wells, who worked on simulations, to develop a joint experimental and computational approach to materials chemistry.
Insilication: the core idea
The central concept is to create a protective silica “coat” around vaccine proteins to prevent thermal unfolding, a process that leads to loss of activity. Satbhaiva explains that vaccines are mainly proteins or virus-like particles that rely on their three-dimensional structure for function. When stored above 2–8°C, proteins can unfold and lose efficacy. Her inspiration draws from marine diatoms that synthesize a silica shell around their bodies; by mimicking this bespoke geometry, she envisioned a protective coat that would not interfere with the protein’s function while enhancing stability and thermal tolerance.
The insilication method and early tests
The insilication process involves growing a tailored silica shell around a protein. The shell is designed to fit the molecular shape, effectively acting as a straightjacket that limits molecular motion and unfolding. This work progressed from model proteins to vaccines. In 2015, coated proteins remained biologically active at room temperature, even when subjected to harsh conditions that would degrade uncoated proteins. The team conducted aggressive testing by boiling proteins to demonstrate the protective effect, showing that uncoated proteins degraded while coated ones retained function. The path to verifying the coating’s protective role involved challenging measurements where biology and silica chemistry can conflict; to address this, the team used Diamond Light Source beamtime to observe early insilication in real time, confirming silica growth around proteins within seconds.
From concept to vaccines: the tetanus test
With proof-of-concept established for proteins, the next crucial step was to test whether a real vaccine could survive in the coating. The team sent uncoated and coated tetanus vaccines to collaborators in Newcastle. The coated vaccine produced a normal immune response in mice, while the uncoated vaccine elicited little or no immune response, indicating spoilage in the absence of the protective coat. This experiment provided a compelling demonstration that insilication could preserve vaccine function outside controlled refrigeration conditions.
Safety, biocompatibility, and animal studies
Safety assessments included animal studies to check for silica accumulation and biocompatibility. The silica used is described as highly biocompatible, with the body capable of excreting excess silica naturally. No significant accumulation was observed in animal models, suggesting a favorable safety profile for the material in the context of vaccine administration. The coating is also inexpensive, an important factor for global health applications where cost is a barrier to wide adoption.
The COVID-19 turning point and entrepreneurship
The pandemic dramatically reshaped the vaccine landscape and underscored logistical challenges in vaccine distribution. Satbhaiva notes that during COVID-19, many researchers urged the formation of a company, and she, along with her husband, co-founded Ensiliatec, a Bath University spin-out, in 2021. The aim is to translate insilication from a laboratory concept into a platform that can stabilise vaccines for human and animal use. The company approach aligns with the broader mission to deliver thermally stable vaccines that can be delivered through standard mail or by drone, bypassing the cold chain entirely in some contexts.
What comes next and global impact
The researchers anticipate progressing insilication towards clinical trials in the next 1–2 years, with a potential timeline for thermally stable vaccines in humans within five to six years. The implications for global health are substantial: thermally stable vaccines could reach remote or infrastructurally challenged regions more reliably, reduce waste, and enable cost reductions for manufacturers. Satbhaiva emphasizes the potential to deliver vaccines in envelopes, by post, or via drones, transforming how vaccines are distributed and administered across the globe.
Concluding reflections
The discussion leaves the listener with a sense of a rigorous, iterative scientific process spanning decades, from educational challenges in Kyrgyzstan to cutting-edge materials science in Bath. It highlights how cross-disciplinary collaboration, patience, and persistence can yield a transformative approach to a long-standing public health problem. The episode closes by reaffirming the BBC Inside Science commitment to exploring credible science with real-world relevance and to communicating the human stories behind scientific innovation.